Fenfluramine hydrochloride is in clinical development as a treatment for paediatric and adult patients with Lennox-Gastaut syndrome. Lennox-Gastaut syndrome is a rare and severe form
of epilepsy that is most commonly found in children. It is characterised by slow mental development and various types of seizures that are difficult to treat. As patients enter into
adulthood, the emergent comorbidities associated with the syndrome (such as impaired mobility, learning and behaviour) become more apparent and add further burden to the
patient and their careers, alongside management of their seizures. Lennox-Gastaut syndrome can be difficult to diagnose when children are young due to the evolving nature of
the seizures experienced. Lennox-Gastaut syndrome is highly resistant to antiepileptic drugs.
Fenfluramine belongs to a class of drugs called the selective serotonin releasing agonists which stimulates multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may also act on other receptors and these actions may help to reduce the frequency of seizures. When added to other standard anti-epileptic treatments, fenfluramine hydrochloride has shown preliminary evidence of reducing seizure frequency. If licensed, fenfluramine hydrochloride may offer an additional treatment option for patients with Lennox-Gastaut syndrome.
Lacosamide is a medicinal product that is being developed for the treatment of Primary Generalised Tonic-Clonic Seizures (PGTCS). Epilepsy is a neurological disorder that is characterised by an imbalance in the excitation and inhibition of the brain and this imbalance causes a phenomenon known as a seizure. Seizures are brief increases in electrical activity within …